Kazia Financial Statements From 2010 to 2025

KZIA Stock  USD 7.57  0.43  5.37%   
Kazia Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kazia Therapeutics' valuation are provided below:
Gross Profit
1.8 M
Market Capitalization
85.8 M
Enterprise Value Revenue
3.1 K
Revenue
1.8 M
Earnings Share
(12.67)
We have found one hundred twenty available fundamental ratios for Kazia Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kazia Therapeutics last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of December 28, 2025, Market Cap is expected to decline to about 8.5 M. In addition to that, Enterprise Value is expected to decline to about 7.4 M

Kazia Therapeutics Total Revenue

39,900

Check Kazia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kazia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 2.3 K or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 2.89, Dividend Yield of 0.0 or Days Sales Outstanding of 17.98. Kazia financial statements analysis is a perfect complement when working with Kazia Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Kazia Stock
Check out the analysis of Kazia Therapeutics Correlation against competitors.

Kazia Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.8 M6.1 M26.5 M
Pretty Stable
Other Current Liabilities8.4 MM4.3 M
Slightly volatile
Total Current Liabilities7.8 M14.1 M6.7 M
Slightly volatile
Accounts Payable5.9 M5.6 M2.3 M
Slightly volatile
Cash4.1 M4.3 M13.2 M
Slightly volatile
Non Current Assets Total1.1 M1.1 M10.5 M
Slightly volatile
Cash And Short Term Investments4.1 M4.3 M13.2 M
Slightly volatile
Net Receivables85.5 K90 K480.3 K
Slightly volatile
Common Stock Total Equity115.2 M72.3 M110.1 M
Slightly volatile
Common Stock Shares Outstanding1.2 M1.1 M393.6 K
Slightly volatile
Liabilities And Stockholders Equity5.8 M6.1 M26.4 M
Pretty Stable
Total Liabilities11.6 M14.4 M10.6 M
Slightly volatile
Total Current Assets4.7 M4.9 M16 M
Slightly volatile
Intangible AssetsM1.1 M8.9 M
Slightly volatile
Common Stock113.9 M123 M119.7 M
Slightly volatile
Capital Stock89.9 M123 M59.7 M
Slightly volatile

Kazia Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M934 K1.1 M
Slightly volatile
Selling General Administrative8.6 M8.7 MM
Slightly volatile
Total Revenue39.9 K42 K3.3 M
Slightly volatile
Other Operating Expenses21.7 M14.3 M17.5 M
Slightly volatile
Research Development10.7 M7.3 M9.4 M
Slightly volatile
Total Operating Expenses16.8 M14.3 M15.2 M
Slightly volatile
Selling And Marketing Expenses108.6 K114.3 K527.9 K
Slightly volatile
Interest Income76.7 K72 K163 K
Slightly volatile
Reconciled Depreciation1.6 M934 K1.4 M
Pretty Stable

Kazia Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.6 M1.7 M11.9 M
Pretty Stable
Depreciation1.2 M934 K1.1 M
Slightly volatile
End Period Cash Flow4.1 M4.3 M12.9 M
Slightly volatile
Stock Based Compensation716.7 K653 K616 K
Pretty Stable
Issuance Of Capital Stock12.8 M14.8 M7.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.893.057.4 K
Slightly volatile
Days Sales Outstanding17.9818.93192
Pretty Stable
Average Payables697.8 K734.6 K1.1 M
Slightly volatile
Stock Based Compensation To Revenue0.20.21167
Slightly volatile
Capex To Depreciation0.0090.00950.3034
Slightly volatile
Sales General And Administrative To Revenue5.025.291.4 K
Slightly volatile
Research And Ddevelopement To Revenue6.446.782.8 K
Slightly volatile
Capex To Revenue0.00110.00120.1133
Slightly volatile
Cash Per Share3.773.97307
Slightly volatile
Intangibles To Total Assets0.670.640.4429
Slightly volatile
Current Ratio0.260.274.9645
Slightly volatile
Receivables Turnover14.8415.62134
Very volatile
Capex Per Share0.130.1427.7494
Slightly volatile
Average Receivables41.8 K44 K399 K
Slightly volatile
Revenue Per Share5.265.53130
Slightly volatile
Interest Debt Per Share1.441.5230.7963
Slightly volatile
Debt To Assets0.02510.02640.0922
Slightly volatile
Graham Number0.750.840.9202
Slightly volatile
Operating Cycle22.9824.19199
Pretty Stable
Ebt Per Ebit0.770.860.9542
Very volatile
Long Term Debt To Capitalization3.0E-43.0E-40.0022
Slightly volatile
Quick Ratio0.260.274.943
Slightly volatile
Cash Ratio0.07020.07394.4536
Slightly volatile
Cash Conversion Cycle17.9818.93286
Very volatile
Days Of Sales Outstanding17.9818.93192
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.161.151.0387
Very volatile
Fixed Asset Turnover16.5811.821.1853
Slightly volatile
Debt Ratio0.02510.02640.0922
Slightly volatile
Price Sales Ratio2.893.057.4 K
Slightly volatile
Asset Turnover0.240.120.1196
Pretty Stable

Kazia Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.5 MM34.4 M
Very volatile

Kazia Fundamental Market Drivers

Kazia Upcoming Events

4th of January 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View
29th of August 2024
Next Fiscal Year End
View
30th of June 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About Kazia Therapeutics Financial Statements

Kazia Therapeutics stakeholders use historical fundamental indicators, such as Kazia Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Kazia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kazia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Kazia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kazia Therapeutics Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.6 M-1.5 M
Total Revenue42 K39.9 K
Stock Based Compensation To Revenue 0.21  0.20 
Sales General And Administrative To Revenue 5.29  5.02 
Research And Ddevelopement To Revenue 6.78  6.44 
Revenue Per Share 5.53  5.26 
Ebit Per Revenue(14.18)(14.89)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Kazia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kazia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kazia Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kazia Therapeutics Ltd Stock:
Check out the analysis of Kazia Therapeutics Correlation against competitors.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kazia Therapeutics. If investors know Kazia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kazia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.67)
Revenue Per Share
1.669
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.64)
Return On Equity
(38.92)
The market value of Kazia Therapeutics is measured differently than its book value, which is the value of Kazia that is recorded on the company's balance sheet. Investors also form their own opinion of Kazia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kazia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kazia Therapeutics' market value can be influenced by many factors that don't directly affect Kazia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kazia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kazia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kazia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.